Mar. 28, 2003 A new non-invasive therapy for liver cancer patients who cannot be helped by surgery or organ transplantation is being evaluated by researchers at the Indiana University School of Medicine. The Phase I clinical trial at the IU Cancer Center uses extracranial stereotactic radioablation (SRA) as a potential new treatment for hepatocelluar carcinoma, a cancer that originates in the liver, or for liver metastasis from other sites.
The technique evaluates the effects of escalating doses of radiation, which delivers highly focused, precisely targeted, radiation to destroy tumors with minimal damage to surrounding health tissues.
For this procedure, a 3-D computer generated grid system is used to precisely map the tumor location where the therapy will be directed. The patient is positioned in a specially fitted, lightweight body frame that allows perfect immobilization of the patient and stereotactic target localization which is essential in order to accurately deliver the radiation to the target with high precision.
The patient then receives multiple "shots" of photon beams produced by a linear accelerator, a technology similarly used in Gamma Knife radiosurgery, which has been highly effective in treating brain tumors.
"SRA may prove to be an option for patients with liver metastases who are not good candidates for conventional therapy," notes principal investigator Higinia Cardenes, M.D., Ph.D., associate clinical professor in the IU Department of Radiation Oncology.
Adds Dr. Cardenes, "This technique is entirely non-invasive and makes it very attractive when compared with currently available therapies for the same patient population such as radio frequency ablation or chemoembolization, which is the delivery of drugs through the hepatic artery directly to the tumor followed by blocking the artery."
Hepatocellular carcinoma is becoming a common clinical problem and its incidence is on the upswing in the United States because of the hepatitis C virus, which causes inflammation of the liver.
"In Phase I of the study we are evaluating the toxicity of the therapy on patients," says Dr. Cardenes. "Our end goal is to determine if higher doses allowed with SRA kill the tumor without damaging healthy tissue or causing other side effects. We will closely monitor each patient's response, toxicity derived from the therapy and, of course, final outcome in terms of tumor control and patient's survival, in order to compare the effectiveness of this treatment with other therapies." The SRA study also is being conducted at the University of Colorado Cancer Center. For possible enrollment in the trial, contact Tia Whitford at 317-278-7267.
On The Web:
Indiana University Cancer Center http://iucc.iu.edu/
IU Clinical Trials Program http://medicine.iupui.edu/ctp/
IU School of Medicine http://www.medicine.indiana.edu
Other social bookmarking and sharing tools:
The above story is based on materials provided by Indiana University.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.